^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IFNG elevation

    i
    Other names: IFNG , Interferon gamma
    Entrez ID:
    3458
    Related biomarkers:
    Expression
    Others
    4ms
    High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma (ESMO 2024)
    To address the question of whether the IFNg can be analyzed using primary tumor material (P-IFNg) instead of LN-IFNg or, in the case of incongruencies, has a higher predictive value when combined with LN-IFNg, we analyzed the IFNg signature in paired samples (P and LN) from stage III melanoma pts. Paraffin primary tumor tissue from pts with stage III melanoma, treated in the OpACIN-neo, PRADO and DONIMI trials (neoadjuvant anti-PD1 +/- anti-CTLA4 +/- domatinostat), was retrospectively analyzed with the nanostring nCounter PanCancer immune profiling panel and compared to fresh frozen LN biopsies. Our results suggest that pts with concurrently high IFNg-signature expressions (high IFNg in P and LN) have a better outcome than LN-IFNg high pts only. If confirmed, these findings could inform treatment selection and prognosis.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • IFNG (Interferon, gamma)
    |
    BRAF mutation • IFNG expression • IFNG elevation
    |
    nCounter® PanCancer Immune Profiling Panel
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)
    1year
    Pegylated Long-Acting Interferon Gamma Treatment Enhances MHC Class II Expression and the Graft-Versus-Leukemia Effect in Preclinical Models of AML Relapse (ASH 2023)
    In addition, mice treated with peg-IFNG had significantly improved survival compared to control groups (median survival 79 days compared to 63 days and 67 days, p<0.05 by Log-Rank test). Together, these findings suggest that long-acting IFNG analogues may effectively enhance GvL in AML patients after HCT.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • CIITA (Class II Major Histocompatibility Complex Transactivator) • GLI2 (GLI Family Zinc Finger 2)
    |
    IFNG expression • MHC-II expression • IFNG elevation
    1year
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=21, Completed, National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jun 2023
    Trial completion • Trial completion date • Checkpoint inhibition • Checkpoint block
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    1year
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Trial primary completion date: Jan 2024 --> Apr 2023
    Trial primary completion date • Checkpoint inhibition • Checkpoint block
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    over1year
    Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients (ESMO 2023)
    Table: 1121P Conclusions Our results suggest that the IFNg-signature could become a biomarker for treatment decisions in LDH low patients directing towards anti-PD1 monotherapy (in IFNg high patients) versus combination therapy, with either anti-LAG3 or anti-CTLA-4 in IFNg low patients. However, confirmation in larger cohorts and in other combination therapies is needed.
    Clinical • Gene Signature • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    BRAF (B-raf proto-oncogene) • IFNG (Interferon, gamma)
    |
    BRAF wild-type • IFNG-L • LDH-L • IFNG elevation
    over1year
    Secondary immunodeficiencies related to the presence of anti-cytokine autoantibodies. (PubMed, Gac Med Mex)
    Consequently, the detection of ACAA could be important in the diagnosis of patients, particularly in the case of late-onset diseases, in order to decide appropriate treatments. This review presents an overview of current understanding of ACAA-associated secondary immunodeficiencies.
    Review • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CSF2 (Colony stimulating factor 2) • IL17A (Interleukin 17A) • IL22 (Interleukin 22)
    |
    IFNG elevation
    over1year
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition • Checkpoint block
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    2years
    Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma (ASH 2022)
    Treatment with PEG-muIFNg beginning 10 days after allo-HSCT can re-sensitize the alloTr AML1 tumors to allogeneic T cell-mediated killing and provide a significant survival advantage. Ongoing studies are also examining the candidate IFNg signaling pathway genes dysregulated in our model to determine if they are upregulated after PEG-muIFNg treatment. Furthermore, future studies will explore if extending PEG-muIFNgtreatment at the 3.8 ug concentration beyond 2 weeks can enhance GVL activity while limiting lethal GVHD.
    Preclinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • DNMT3A (DNA methyltransferase 1) • IFNG (Interferon, gamma)
    |
    IFNG expression • MHC-II expression • IFNG elevation
    2years
    Potential ferroptosis-related diagnostic and prognostic biomarkers in laryngeal cancer. (PubMed, Eur Arch Otorhinolaryngol)
    Our study identified key genes closely related to ferroptosis in LC, which still need more studies to explore the mechanisms involved and may become effective clinical diagnostic and prognostic biomarkers.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • IFNG (Interferon, gamma) • MUC1 (Mucin 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CA9 (Carbonic anhydrase 9) • NOX4 (NADPH Oxidase 4) • MAPK3 (Mitogen-Activated Protein Kinase 3)
    |
    CDKN2A mutation • IFNG elevation
    2years
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=20, Recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    over2years
    Interferon-gamma Induces Melanogenesis Via Post-Translational Regulation of Tyrosinase. (PubMed, Pigment Cell Melanoma Res)
    Inhibition of IFNG pathway by the JAK1/2 inhibitor ruxolitinib or knocking out Stat1 gene abrogated the IFNG-induced melanogenesis...Moreover, cycloheximide chase assay showed that degradation of TYR was decreased in IFNG-treated cells. These results suggest that the IFNG-STAT1 pathway regulates melanogenesis via regulation of the post-translational processing and protein stability of TYR.
    Journal
    |
    IFNG (Interferon, gamma) • TYRP1 (Tyrosinase Related Protein 1) • DCT (Dopachrome Tautomerase) • MITF (Melanocyte Inducing Transcription Factor)
    |
    IFNG expression • IFNG elevation
    |
    Jakafi (ruxolitinib)
    over2years
    Release of IFN-γ by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. (PubMed, Clin Cancer Res)
    IFN-g release by AML cells induces an immune-regulatory program in MSCs and remodels BM immunological landscape toward Treg induction, contributing to an immunotolerant microenvironment.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    IFNG-L • IDO1 expression • IFNG expression • IFNG elevation
    over2years
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Completed --> Active, not recruiting | Trial completion date: Jan 2022 --> Dec 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    almost3years
    FUNCTIONALITY AND ENDURANCE OF GMP-STANDARD BCMA-CAR-T CELLS AT DIFFERENT TIMEPOINTS (EBMT 2022)
     BCMA-CAR-T cells manufatured under GMP conditions possessed the ability for robust and specific killing of target tumor cells with a higher release of cytokines. Even after 14 or 90 days of cryopreservation, their cytotoxic functions were maintained at the same level. This give clinicians enough time to schedule the timepoint of BCMA CAR-T cell application to the patient.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    IFNG elevation
    almost3years
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=18, Completed, National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Jan 2022
    Trial completion • Trial completion date • Checkpoint inhibition
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    over3years
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Trial primary completion date: Jun 2021 --> Jan 2022
    Clinical • Trial primary completion date • Checkpoint inhibition
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    over3years
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2021
    Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    almost4years
    Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022
    Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    IFNG (Interferon, gamma)
    |
    IFNG elevation
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)